Objective: To evaluate the clinical outcome of frozen-thawed embryo transfer (FET) when using different luteal support schemes. Study Design: Retrospective analysis of FET cycles was performed from June 2013 and December 2013. Infertile women, who underwent FET cycles utilizing embryos cryopreserved on day 3 post-insemination following an initial fresh IVF cycle. Patients were divided into three groups according to the luteal support scheme. Grade A (oral administration of progesterone, n=156), Group B (vaginal administration of progesterone, n=345), Group C (dissolved progesterone in oil with intramuscular infection, n=885), and group C wasdivided into two subgroups according to with (subgroup C1, n=521) or without (subgroup C2 ,n=364) human chorionic gonadotrophin (hCG) injected intramuscularly. The authors compared patients' characteristics and the pregnancy outcomes of each group. Results: There was no difference in the patient characteristics of each group. There was no difference in the implantation rate or clinical and ongoing pregnancy rate among oral, vaginal, and intramuscular progesterone groups. The abortion and ectopic pregnancy rates were not significantly different among the three groups. Conclusion: Oral progesterone in the FET cycles is convenient and has similar pregnancy outcomes compared with intramuscular or vaginal administration.